OriCiro Genomics K.K. is a company that specializes in cell-free DNA synthesis and amplification technologies, according to a Jan. 4 Moderna news release.
“With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,” Stéphane Bancel, CEO of Moderna, said in the release. “OriCiro’s technology strategically complements our manufacturing expertise and further accelerates our research and development engine.”
